232 related articles for article (PubMed ID: 11467325)
1. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility.
Thrailkill KM
Diabetes Technol Ther; 2000; 2(1):69-80. PubMed ID: 11467325
[TBL] [Abstract][Full Text] [Related]
2. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
[TBL] [Abstract][Full Text] [Related]
5. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus.
Bereket A; Lang CH; Wilson TA
Horm Metab Res; 1999; 31(2-3):172-81. PubMed ID: 10226799
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.
Mohamed-Ali V; Pinkney J
Treat Endocrinol; 2002; 1(6):399-410. PubMed ID: 15832492
[TBL] [Abstract][Full Text] [Related]
7. [Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy].
Peczyńska J; Urban M; Głowińska B; Urban B
Pol Merkur Lekarski; 2003 Apr; 14(82):336-9. PubMed ID: 12868196
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: friends or foes?
Orskov H
Metabolism; 1996 Aug; 45(8 Suppl 1):91-5. PubMed ID: 8769394
[TBL] [Abstract][Full Text] [Related]
9. Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization.
Hanaire-Broutin H; Sallerin-Caute B; Poncet MF; Tauber M; Bastide R; Rosenfeld R; Tauber JP
Diabetes Metab; 1996 Jul; 22(4):245-50. PubMed ID: 8767170
[TBL] [Abstract][Full Text] [Related]
10. The IGF system in metabolism regulation.
Binoux M
Diabete Metab; 1995 Dec; 21(5):330-7. PubMed ID: 8586149
[TBL] [Abstract][Full Text] [Related]
11. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
Dunger DB; Acerini CL
Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221
[TBL] [Abstract][Full Text] [Related]
12. Childhood and adolescent diabetes.
Dunger DB; Regan FM; Acerini CL
Endocr Dev; 2005; 9():107-120. PubMed ID: 15879693
[TBL] [Abstract][Full Text] [Related]
13. Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy.
Vasylyeva TL; Ferry RJ
Diabetes Res Clin Pract; 2007 May; 76(2):177-86. PubMed ID: 17011663
[TBL] [Abstract][Full Text] [Related]
14. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
[TBL] [Abstract][Full Text] [Related]
15. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats.
Fielder PJ; Mortensen DL; Mallet P; Carlsson B; Baxter RC; Clark RG
Endocrinology; 1996 May; 137(5):1913-20. PubMed ID: 8612531
[TBL] [Abstract][Full Text] [Related]
16. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus.
Janssen JA; Jacobs ML; Derkx FH; Weber RF; van der Lely AJ; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):2809-15. PubMed ID: 9284701
[TBL] [Abstract][Full Text] [Related]
17. Mecasermin (recombinant human insulin-like growth factor I).
Rosenbloom AL
Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
Ranke MB
Trends Endocrinol Metab; 2005; 16(4):190-7. PubMed ID: 15860416
[TBL] [Abstract][Full Text] [Related]
19. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
[TBL] [Abstract][Full Text] [Related]
20. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus.
Bach MA; Chin E; Bondy CA
J Clin Endocrinol Metab; 1994 Oct; 79(4):1040-5. PubMed ID: 7525624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
